National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Cost-effectiveness of certolizumab pegol (Cimzia®) for the treatment of moderate to severe rheumatoid arthritis.

Pharmacoeconomic Evaluation

Commenced Completed Outcome
13/03/2010 02/09/2010 Reimbursement not Recommended.

The review group did not consider certolizumab cost-effective at the submitted price in September 2010.

Certolizumab pegol (Cimzia) Summary

The HSE has approved reimbursement following confidential price negotiations.